Health
Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection – News-Medical.Net
Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Enzyme linked immunosorbent assays (“ELISAs”) are very common research tools used to detect and quantify a target of interest in a wide range of samples. Using the same Affimer reagents that are incorporated into its rapid coronavirus saliva test…
-
Noosa News24 hours agoBrisbane man, 39, dies after stabbing at inner city home in early morning attack, prompting investigation
-
General23 hours agoFederal Labor makes $100m Canberra convention centre funding pledge for planning, new aquatic centre
-
Noosa News19 hours agoBrisbane’s covert cameras catching more than just litterbugs
-
Business4 hours ago1 ASX dividend stock down 43% I’d buy right now